SCHEMBL3841307

SCHEMBL3841307

O=C(O)c1sc(-c2ccc(F)cc2)nc1CCO

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.47
KDM4E B2RXH2 3/20 0.46
RAB9A P51151 3/20 0.46
GAA P10253 1/20 0.46
PTGDR2 Q9Y5Y4 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
LMNA P02545 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CDC7 O00311 1/20 0.41
DBF4 Q9UBU7 1/20 0.41
ALOX5 P09917 1/20 0.41
MAPT P10636 2/20 0.40
MAPK14 Q16539 1/20 0.40
TP53 P04637 1/20 0.40
TARBP2 Q15633 1/20 0.40
PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3837596 0.87 SMN1; SMN2 (0.58) TRPM8KDM4ERAB9AGAAPTGDR2
SCHEMBL12154280 0.86 RAB9A (0.64) TRPM8KDM4ERAB9AGAASMN1; SMN2
SCHEMBL2073067 0.86 RAB9A (0.61) TRPM8KDM4ERAB9AGAAPTGDR2
SCHEMBL3841396 0.85 ALDH1A1 (0.52) KDM4ERAB9AGAASMN1; SMN2NPC1
SCHEMBL2073958 0.83 PTGDR2 (0.52) KDM4ERAB9AGAAPTGDR2SMN1; SMN2
SCHEMBL6602368 0.78 DCK (0.53) TRPM8LMNAALOX5MAPTTP53
SCHEMBL15049252 0.77 CDC7 (0.67) TRPM8KDM4ERAB9AGAAPTGDR2
SCHEMBL3436647 0.76 RAB9A (0.77) TRPM8KDM4ERAB9AGAASMN1; SMN2
SCHEMBL3837371 0.76 KMT2A (0.54) TRPM8KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL6602682 0.75 DCK (0.55) TRPM8PTGDR2LMNAMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828207-B1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-28 EP disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R TRPM8 716/4885KDM4E 1557/4885RAB9A 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.